
## Alessia Aloisi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5749668/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A novel algorithm to implement the molecular classification according to the new ESGO/ESTRO/ESP 2020 guidelines for endometrial cancer. International Journal of Gynecological Cancer, 2022, 32, 993-1000.	2.5	14
2	Oncologic Outcomes of Robotic Radical Hysterectomy (RRH) for Patients with Early-Stage Cervical Cancer: Experience at a Referral Cancer Center. Annals of Surgical Oncology, 2021, 28, 1819-1829.	1.5	7
3	ASO Author Reflections: Robotic Radical Hysterectomy for Patients with Early-Stage Cervical Cancer: Oncologic Outcomes. Annals of Surgical Oncology, 2021, 28, 1830-1831.	1.5	0
4	ASO Author Reflections: Robotically Assisted Gynecologic Surgery in the Frail Elderly: Analysis of Perioperative Outcomes. Annals of Surgical Oncology, 2020, 27, 3781-3782.	1.5	0
5	Robotic Surgery in the Frail Elderly: Analysis of Perioperative Outcomes. Annals of Surgical Oncology, 2020, 27, 3772-3780.	1.5	16
6	ls Robotic-Assisted Surgery Safe in the Elderly Population? An Analysis of Gynecologic Procedures in Patients ≥ 65AYears Old. Annals of Surgical Oncology, 2019, 26, 244-251.	1.5	18
7	Minimally invasive hysterectomy surgery rates for endometrial cancer performed at National Comprehensive Cancer Network (NCCN) Centers. Gynecologic Oncology, 2018, 148, 480-484.	1.4	60
8	Prospective Comparative Study of Laparoscopic Narrow Band Imaging (NBI) Versus Standard Imaging in Gynecologic Oncology. Annals of Surgical Oncology, 2018, 25, 984-990.	1.5	12
9	The role of macroplastique implantation in the management of occult urinary stress incontinence. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 225, 124-128.	1.1	2
10	Long-Term Oncologic Outcomes of Uterine-Preserving Surgery in Young Women With Stage lb1 Cervical Cancer. International Journal of Gynecological Cancer, 2018, 28, 1350-1359.	2.5	16
11	ASO Author Reflections: Narrow-Band Imaging: A Novel Imaging Method in Minimally Invasive Surgery. Annals of Surgical Oncology, 2018, 25, 880-881.	1.5	0
12	Patterns of FIRST recurrence of stage IIIC1 endometrial cancer with no PARAAORTIC nodal assessment. Gynecologic Oncology, 2018, 151, 395-400.	1.4	14
13	Less versus more radical surgery in stage IB1 cervical cancer: A population-based study of long-term survival. Gynecologic Oncology, 2018, 150, 44-49.	1.4	30
14	Bilateral Otorrhagia after Robotically Assisted Gynecologic Surgery in the Setting of a Reduced Trendelenburg Position and Low-Pressure Pneumoperitoneum: A Case Report and Review of the Literature. Journal of Minimally Invasive Gynecology, 2017, 24, 1229-1233.	0.6	5
15	Validation of REM score to predict endometrial cancer in patients with ultrasound endometrial abnormalities: results of a new independent dataset. Medical Oncology, 2017, 34, 82.	2.5	11
16	The Tip of the Iceberg. Journal of Clinical Oncology, 2017, 35, 801-802.	1.6	1
17	Reference Charts for Fetal Cerebellar Vermis Height: A Prospective Cross-Sectional Study of 10605 Fetuses. PLoS ONE, 2016, 11, e0147528.	2.5	16
18	Ten years of HPV vaccines: State of art and controversies. Critical Reviews in Oncology/Hematology, 2016, 102, 65-72.	4.4	52

ALESSIA ALOISI

#	Article	IF	CITATIONS
19	Patients treated with neoadjuvant chemotherapyÂ+Âradical surgeryÂ+Âadjuvant chemotherapy in locally advanced cervical cancer: long-term outcomes, survival and prognostic factors in a single-center 10-year follow-up. Medical Oncology, 2016, 33, 110.	2.5	14
20	Preoperative local staging of endometrial cancer: the challenge of imaging techniques and serum biomarkers. Archives of Gynecology and Obstetrics, 2016, 294, 1291-1298.	1.7	25
21	Role of paroxetine in the management of hot flashes in gynecological cancer survivors: Results of the first randomized single-center controlled trial. Gynecologic Oncology, 2016, 143, 584-588.	1.4	20
22	The role of HE4 in endometrial cancer recurrence: how to choose the optimal follow-up program. Tumor Biology, 2016, 37, 4973-4978.	1.8	33
23	Economic Impact Among Family Caregivers of Patients With Advanced Ovarian Cancer. International Journal of Gynecological Cancer, 2015, 25, 1541-1546.	2.5	27
24	Chemotherapy as Adjuvant Treatment for Intermediate-High Risk Early-Stage Endometrial Cancer. International Journal of Gynecological Cancer, 2015, 25, 1418-1423.	2.5	7
25	Supplementation with a dietary multicomponent (Lafergin�) based on Ferric Sodium EDTA (Ferrazone�): results of an observational study. Journal of Prenatal Medicine, 2015, 9, 1-7.	0.2	7
26	Primary chemotherapy versus primary surgery for ovarian cancer. Lancet, The, 2015, 386, 2142.	13.7	2
27	Quality of Life in Platinum-Sensitive Recurrent Ovarian Cancer: Chemotherapy Versus Surgery Plus Chemotherapy. Annals of Surgical Oncology, 2015, 22, 2387-2394.	1.5	20
28	Utility of tumor marker HE4 as prognostic factor in endometrial cancer: a single-center controlled study. Tumor Biology, 2015, 36, 4151-4156.	1.8	37
29	Effects of exogenous progesterone on fetal nuchal translucency: an observational prospective study. American Journal of Obstetrics and Gynecology, 2015, 212, 335.e1-335.e7.	1.3	19
30	Influence of pneumoperitoneum pressure on surgical field during robotic and laparoscopic surgery: a comparative study. Archives of Gynecology and Obstetrics, 2015, 291, 865-868.	1.7	24
31	A Predictive Score for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer (SeC-Score): A Single-Centre, Controlled Study for Preoperative Patient Selection. Annals of Surgical Oncology, 2015, 22, 4217-4223.	1.5	20
32	A randomized controlled trial comparing four versus six courses of adjuvant platinum-based chemotherapy in locally advanced cervical cancer patients previously treated with neo-adjuvant chemotherapy plus radical surgery. Gynecologic Oncology, 2015, 139, 433-438.	1.4	16
33	Reply. American Journal of Obstetrics and Gynecology, 2015, 213, 438.	1.3	0
34	The impact of gynecologic oncology training in the management of cancer patients: is it really necessary? A prospective cohort study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 184, 19-23.	1.1	7
35	Adjuvant chemotherapy after primary treatments for cervical cancer: a critical point of view and review of the literature. Expert Review of Anticancer Therapy, 2014, 14, 431-439.	2.4	11
36	Reference Charts for Fetal Corpus Callosum Length. Journal of Ultrasound in Medicine, 2014, 33, 1065-1078.	1.7	45

ALESSIA ALOISI

#	Article	IF	CITATIONS
37	A critical review on HE4 performance in endometrial cancer: where are we now?. Tumor Biology, 2014, 35, 881-887.	1.8	46
38	Feasibility and safety of carboplatin plus paclitaxel as neoadjuvant chemotherapy for locally advanced cervical cancer: a pilot study. Tumor Biology, 2014, 35, 2741-2746.	1.8	19
39	Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer?. Tumor Biology, 2014, 35, 7009-7015.	1.8	42
40	The effects of giving patients verbal or written pre-operative information in gynecologic oncology surgery: a randomized study and the medical-legal point of view. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2014, 177, 67-71.	1.1	41
41	Success rates, quality of life, and feasibility of sacral nerve stimulation in elderly patients: 1-year follow-up. International Urogynecology Journal, 2013, 24, 789-794.	1.4	21
42	RE: Does treatment progress follow the Cinderella principle?. Gynecologic Oncology, 2013, 129, 266-267.	1.4	0
43	Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma?. Gynecologic Oncology, 2013, 128, 579-583.	1.4	60
44	The role of novel biomarker HE4 in endometrial cancer: a case control prospective study. Tumor Biology, 2013, 34, 571-576.	1.8	88
45	Novel mutation of the sexâ€determining region on the Y chromosome in a 46,XY female patient with monolateral dysgerminoma: A case report. Journal of Obstetrics and Gynaecology Research, 2013, 39, 442-445.	1.3	5
46	REM (Risk of Endometrial Malignancy): A Proposal for a New Scoring System to Evaluate Risk of Endometrial Malignancy. Clinical Cancer Research, 2013, 19, 5733-5739.	7.0	28
47	Does Extensive Upper Abdomen Surgery During Primary Cytoreduction Impact on Long-term Quality of Life?. International Journal of Gynecological Cancer, 2013, 23, 442-447.	2.5	15
48	Does HE4 have a role as biomarker in the recurrence of ovarian cancer?. Tumor Biology, 2012, 33, 2117-2123.	1.8	54
49	Neoadjuvant chemotherapy plus radical surgery followed by chemotherapy in locally advanced cervical cancer. Gynecologic Oncology, 2012, 127, 290-296.	1.4	83
50	Suburethral sling in autoimmune patients: complications, quality of life, and success rate. International Urogynecology Journal, 2012, 23, 453-457.	1.4	2